Autobahn Therapeutics

NEWS

Biotech Beach

Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B

This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.

June 9, 2020

·

2 min read

·

JOBS

IN THE PRESS

Business

Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders

September 14, 2021

·

4 min read

FDA

Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy

August 2, 2021

·

2 min read

Deals

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

May 11, 2021

·

2 min read

Drug Development

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

April 17, 2021

·

3 min read

Biotech Beach

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

·

1 min read

Business

Autobahn Therapeutics Strengthens its Team to Support its Continued Growth

January 5, 2021

·

3 min read

Business

Autobahn Therapeutics Appoints Business Leader, Scott Forrest, Ph.D., as Chief Business Officer

July 15, 2020

·

3 min read

Deals

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders

June 9, 2020

·

4 min read